Exploration of Indications and Establishment of a Primary Prevention Prediction Model for Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors, and Investigation of the Mechanisms of Related Influencing Factors
Latest Information Update: 01 Apr 2026
At a glance
- Drugs Antineoplastics (Primary) ; Trilaciclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 01 Apr 2026 New trial record